SNIPR Advances SNIPR001 Into Phase 2 for E. coli Prevention
COPENHAGEN, Denmark — September 17, 2026 SNIPR announced that the first patient has been enrolled in Part 2 of...
Escherichia coli
Advertisement
Intelligent Bio Solutions Completes Clinical Study for FDA 510(k) Submission
NEW YORK, August 11, 2026 Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for...
SNIPR Advances SNIPR001 With Compassionate-Use Clinical Evidence
COPENHAGEN, Denmark, August 12, 2026 SNIPR announced new clinical evidence supporting the translational potential of SNIPR001, its engineered CRISPR-enhanced...
Boehringer Introduces LENZELTA Vaccine for Mastitis Control
INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...
Advertisement
